Difficulty: Medium
Average Score: 94%
Practice
The following may be effective in the management of severe psoriasis:
Correct answer
A
Rationale
The correct answer is A) Weekly methotrexate for the management of severe psoriasis. Methotrexate is a systemic medication that is commonly used in the treatment of psoriasis due to its ability to slow down the rapid turnover of skin cells in psoriatic lesions. It is effective in reducing inflammation and controlling the symptoms of severe psoriasis.
Option B) Erythromycin is an antibiotic that is not typically used in the management of psoriasis. Psoriasis is an inflammatory autoimmune skin condition, and erythromycin does not target the underlying immune system dysfunction that drives psoriasis.
Option C) Efalizumab is a biologic medication that was previously used for psoriasis. However, it has been withdrawn from the market due to safety concerns, including the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection.
Option D) Nateglinide is a medication used to treat type 2 diabetes by stimulating insulin release from the pancreas. It is not indicated for the treatment of psoriasis as it does not address the underlying inflammatory processes in the skin.
In an educational context, it is crucial for healthcare providers to understand the appropriate pharmacological management of psoriasis based on the latest evidence and guidelines. Methotrexate is a first-line systemic therapy for severe psoriasis and understanding its mechanism of action and efficacy can help healthcare professionals make informed decisions in the treatment of this chronic skin condition.
Option B) Erythromycin is an antibiotic that is not typically used in the management of psoriasis. Psoriasis is an inflammatory autoimmune skin condition, and erythromycin does not target the underlying immune system dysfunction that drives psoriasis.
Option C) Efalizumab is a biologic medication that was previously used for psoriasis. However, it has been withdrawn from the market due to safety concerns, including the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection.
Option D) Nateglinide is a medication used to treat type 2 diabetes by stimulating insulin release from the pancreas. It is not indicated for the treatment of psoriasis as it does not address the underlying inflammatory processes in the skin.
In an educational context, it is crucial for healthcare providers to understand the appropriate pharmacological management of psoriasis based on the latest evidence and guidelines. Methotrexate is a first-line systemic therapy for severe psoriasis and understanding its mechanism of action and efficacy can help healthcare professionals make informed decisions in the treatment of this chronic skin condition.